New concepts in organ transplantation

Transplantation Proceedings

Volumn 36, Issue 5, 2004, Pages 1228-1231

  Praditpornsilpa, K ^a   Avihingsanon, Y ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR ANTAGONIST; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PEPTIDE; POLYCLONAL ANTIBODY; RAPAMYCIN; SELECTIN ANTAGONIST; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADHESION; BONE MARROW SUPPRESSION; BRADYCARDIA; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE DEFICIENCY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MIGRATION; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SINGLE DRUG DOSE; TOXICITY; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 3142526241     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.05.002     Document Type: Article

References (24)

1. Dunn J., Golden D., Van Buren C.T., et al. Causes of graft loss beyond two years in the cyclosporine era. Transplantation. 49:1990;349
2. Mcever R.P. Leukocyte adhesion through selectin under flow. Immunologist. 6:1998;61
3. Snapp K.R., Ding H., Atkins K., et al. A novel P-selectin glycoprotein ligand-1 monoclonal antibidy recognizes an epitope within the tyrosine sulphate motif of human PSGL-1 and blocks recognition of both P- and L- selectin. Blood. 91:1998;154
4. Palma-Vargas J.M., Toledo-Pereya L., Dean R.E., et al. Small molecule selectin inhibitor protects against liver inflammatory response after ischemis and reperfusion. J Am Coll Surg. 185:1997;365
5. Dulkanchainum T.S., Goss J.A., Imagawa D.K., et al. Reduction of hepatic ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-1. Ann Surg. 227:1998;832
6. Calne R.Y., White D.J., Thiru S., et al. Cyclosporine A in patients receiving renal allografts from cadaveric donors. Lancet. 2:1985;1323
7. Stepkowski S.M., Wang M.E., Condon T.P., et al. Protection against allograft rejection with ICAM-1 antisense oligideoxynucleotides. Transplantation. 66:1998;699
8. Chen W., Bennett C.F., Wang M.E., et al. Perfusion of kidneys with unformulated 'naked' intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury. Transplantation. 68:1999;880
9. Dragun D., Lukitsh I., Tullius S.G., et al. Inhibition of intercellular adhesion molecule-1 with antisense deoxynucleotides prolongs renal allograft survival in the rat. Kideny Int. 54:1998;2113
10. Stepkowski S.M., Chen W., Bennett C.F., et al. Phosphorothioate/ Methoxyrthyl-modified ICAM-1 antisense oliginucleotides improves prevention of ischemic/reperfusion injury. Transplant Proc. 33:2001;3705
11. Ortiz A.M., Troncoso P., Kahan B.D. Prevention of renal ischemic reperfusion injury using FTY 720 and ICAM-1 antisense oligonucleotides. Transplant Proc. 35:2003;1571
12. Suzuki S., Enosawa S., Kakefuda T., et al. A novel immunosuppression, FTY 720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allo-transplantation. Transplantation. 61:1996;200
13. Suzuki S., Enosawa S., Kakefuda T., et al. Long-term grafts acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY 720. Transplant Proc. 28:1996;1375
14. Quesniaux V., Menninger K., Audet L., et al. FTY 720 is efficacious in monkey kidney transplantation. Transplant Proc. 33:2001;2374
15. Brunkhorst R, Neumayer H-H, Hiss M, et al. Human safety and pharmacology of FTY 720. Presented at the 18th Annual Meeting of the American Society of Transplantation, 1999 (Abstract 585)
16. Wang M.E., Tejpal N., Qy X., et al. Immunosuppressive effects of FTY 720 alone or in combination with cyclosporine or sirolimus. Transplantation. 65:1998;899
17. Troncoso P., Stepkowski S.M., Wang M.E., et al. Prophylaxis of acute renal allograft rejection using FTY 720 in combination with subtherapeutic doses of cyclosporine. Transplantation. 67:1999;145
18. Magee C., Sayegh M. Peptide-mediated immunosuppression. Curr Opin Immunol. 9:1997;669
19. 11 alloantigen. Transplantation. 63:1997;662
20. Kirk A.D., Harlan D.M., Armstrong N.N., et al. CTLA 4- Ig and anti-CD 40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 94:1997;8789
21. Vezina C., Kudelski A., Sehgal S.N. Rapamicin (AY-22, 989), a new antifungal antibiotic I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 28:1975;721
22. Stepkowski S.M., Chen H., Daloze P., et al. rapamicin, a potent immunsuppression drug for vascularized heart, kidney, and small bowel transplantation in the rat. Transplantation. 51:1991;22
23. Kahan B.D., Gibbons S., Tejpal N., et al. Synergistic interactions of cyclosporine and rapamicin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation. 51:1991;185
24. Kirken R, Erwin-Cohen R, Behbod F, et al. Tyrphostin Ag 490 blocks activation of Jak 3 and rejection of heart allografts in rats. Presented at the XXV Annual Scientific Meeting of the American Society of Transplantation, 1999 (Abstract 826)